Polish pharmaceutical company Biomed Lublin announced that it has finished production of the first batch of medicine made of plasma obtained from those who recovered from COVID-19 disease.
The medicine, created via the process of the fractionation of plasma from patients who recovered or showed no symptoms of COVID-19 but were infected, contains specific anti-SARS-CoV-2 immunoglobulins. It will be released for non-commercial clinical trials in Q4 2020, according to the company. “If everything goes as planned, in a few months Poland will be the first country in the world with an efficient drug for ‘neutralising the virus,’” Biomed declared.
“We have unequivocally proven that it is possible to produce a drug containing a concentrated dose of such antibodies and it can effectively use human plasma, which, after the fractionation process, can be converted into a drug with a treatment efficiency greater than plasma alone,” Marcin Piróg, the CEO of Biomed said.
“More than 3,000 samples of anti-SARS-CoV-2 immunoglobulin have been produced, which after the completion of the required quality tests, including product stability tests, will be submitted for clinical trials in four centres: in Lublin, Bytom, Białystok and Warsaw,” he added.
A total of 81,673 confirmed cases of the SARS-CoV-2 coronavirus infections were recorded in Poland as of Wednesday morning, including 2,344 fatalities and 65,561 recoveries.
Become a Student Volunteer Journalist…